Restoration of estrogen responsiveness by blocking the HER-2/neu pathway

Lois Witters; Linda Engle; Allan Lipton

doi:10.3892/or.9.6.1163

Restoration of estrogen responsiveness by blocking the HER-2/neu pathway

Lois Witters, Linda Engle, Allan Lipton

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

HER-2/neu gene amplification or protein overexpression is evident in 20-30% of primary breast cancers. Its amplification correlates with poor prognosis. There appears to be an association between HER-2/neu overexpression and estrogen independence. The MCF-7 human breast carcinoma cell line is estrogen-dependent and sensitive to the anti-estrogen, tamoxifen (TAM). This line, when transfected with the HER-2/neu gene, becomes estrogen-independent and resistant to TAM. Blockade of the HER-2/neu receptor with 1-5 nM of the humanized HER-2/neu antibody, Herceptin, restored estrogen, as well as TAM, sensitivity. These results suggest that Herceptin or similar drugs may restore estrogen sensitivity and the administration of a HER-2/neu inhibitor with an anti-estrogen to premenopausal patients should be considered.

Original language	English (US)
Pages (from-to)	1163-1166
Number of pages	4
Journal	Oncology reports
Volume	9
Issue number	6
DOIs	https://doi.org/10.3892/or.9.6.1163
State	Published - Nov 2002

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3892/or.9.6.1163

Cite this

@article{7e11071966ea49e1828244f7e45d2880,

title = "Restoration of estrogen responsiveness by blocking the HER-2/neu pathway",

abstract = "HER-2/neu gene amplification or protein overexpression is evident in 20-30% of primary breast cancers. Its amplification correlates with poor prognosis. There appears to be an association between HER-2/neu overexpression and estrogen independence. The MCF-7 human breast carcinoma cell line is estrogen-dependent and sensitive to the anti-estrogen, tamoxifen (TAM). This line, when transfected with the HER-2/neu gene, becomes estrogen-independent and resistant to TAM. Blockade of the HER-2/neu receptor with 1-5 nM of the humanized HER-2/neu antibody, Herceptin, restored estrogen, as well as TAM, sensitivity. These results suggest that Herceptin or similar drugs may restore estrogen sensitivity and the administration of a HER-2/neu inhibitor with an anti-estrogen to premenopausal patients should be considered.",

author = "Lois Witters and Linda Engle and Allan Lipton",

year = "2002",

month = nov,

doi = "10.3892/or.9.6.1163",

language = "English (US)",

volume = "9",

pages = "1163--1166",

journal = "Oncology reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "6",

}

TY - JOUR

T1 - Restoration of estrogen responsiveness by blocking the HER-2/neu pathway

AU - Witters, Lois

AU - Engle, Linda

AU - Lipton, Allan

PY - 2002/11

Y1 - 2002/11

N2 - HER-2/neu gene amplification or protein overexpression is evident in 20-30% of primary breast cancers. Its amplification correlates with poor prognosis. There appears to be an association between HER-2/neu overexpression and estrogen independence. The MCF-7 human breast carcinoma cell line is estrogen-dependent and sensitive to the anti-estrogen, tamoxifen (TAM). This line, when transfected with the HER-2/neu gene, becomes estrogen-independent and resistant to TAM. Blockade of the HER-2/neu receptor with 1-5 nM of the humanized HER-2/neu antibody, Herceptin, restored estrogen, as well as TAM, sensitivity. These results suggest that Herceptin or similar drugs may restore estrogen sensitivity and the administration of a HER-2/neu inhibitor with an anti-estrogen to premenopausal patients should be considered.

AB - HER-2/neu gene amplification or protein overexpression is evident in 20-30% of primary breast cancers. Its amplification correlates with poor prognosis. There appears to be an association between HER-2/neu overexpression and estrogen independence. The MCF-7 human breast carcinoma cell line is estrogen-dependent and sensitive to the anti-estrogen, tamoxifen (TAM). This line, when transfected with the HER-2/neu gene, becomes estrogen-independent and resistant to TAM. Blockade of the HER-2/neu receptor with 1-5 nM of the humanized HER-2/neu antibody, Herceptin, restored estrogen, as well as TAM, sensitivity. These results suggest that Herceptin or similar drugs may restore estrogen sensitivity and the administration of a HER-2/neu inhibitor with an anti-estrogen to premenopausal patients should be considered.

UR - http://www.scopus.com/inward/record.url?scp=0036835014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036835014&partnerID=8YFLogxK

U2 - 10.3892/or.9.6.1163

DO - 10.3892/or.9.6.1163

M3 - Article

C2 - 12375012

AN - SCOPUS:0036835014

SN - 1021-335X

VL - 9

SP - 1163

EP - 1166

JO - Oncology reports

JF - Oncology reports

IS - 6

ER -

Restoration of estrogen responsiveness by blocking the HER-2/neu pathway

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this